George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.50
Bid: 14.00
Ask: 15.00
Change: 0.50 (3.57%)
Spread: 1.00 (7.143%)
Open: 14.00
High: 15.00
Low: 14.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

Thu, 04th Jan 2024 08:58

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

The FTSE 100 index opened up 28.37 points, or 0.4%, at 7,710.70. The FTSE 250 was up 62.33 points, 0.3%, at 19,388.73, and the AIM All-Share was 0.61 of a point, 0.1%, at 754.76.

Retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

The Cboe UK 100 was up 0.3% at 769.45, the Cboe UK 250 was up 0.4% at 16,841.68, and the Cboe Small Companies was up 0.1% at 14,879.58.

In European equities, the CAC 40 in Paris was up 0.2%, while the DAX 40 in Frankfurt was up 0.3%.

Sterling was quoted at USD1.2687 early Thursday, higher than USD1.2646 at the London equities close on Wednesday. The euro traded at USD1.0938, higher than USD1.0915. Against the yen, the dollar was quoted at JPY143.61, higher than JPY143.50.

In the FTSE 100, Next rose 4.1%. The retailer said full price sales during November and December were better than it anticipated.

In a trading update covering the nine weeks to December 30, Next said full price sales were up 5.7% from a year earlier, which was GBP39 million than its previous guidance of a 2.0% rise for the period.

Next upped its full-year pretax profit guidance by GBP20 million, or 4.0% to GBP905 million compared to last year, saying GBP17 million of the lift comes from the sales beat to date and GBP3 million from an upgraded forecast for full price sales in January.

"Next's Christmas trading update gave investors plenty to be jolly about," said Hargreaves Lansdown analyst Aarin Chiekrie.

"Successfully keeping full-priced sales front and centre to avoid discounts is one of the reasons Next can boast some of the best margins in the sector. But it's a tricky strategy to nail, especially alongside expanding its online presence and introducing third-party brands to its offering."

JD Sports plunged 20%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

"Our key markets have seen increased promotional activity during the peak trading season, driven by a more cautious consumer, but we continue to grow market share," said JD Sports Chief Executive Officer Regis Schultz.

"We are confident in our strategy and we continue to invest in our supply chain, systems and stores, supported by our strong cash generation and healthy balance sheet."

Oil majors BP and Shell rose 1.4% and 0.9% respectively, tracking improved oil performance. Brent oil was trading at USD78.92 a barrel early Thursday, higher than USD78.13 on Wednesday.

In the FTSE 250, Tritax EuroBox gained 2.0%.

The investor in Continental European logistics real estate said it agreed a new five-year lease with an unnamed Scandinavian photovoltaic company to let its 5,007 square metre unit at its 13,611 square metre two-unit development near Stockholm, Sweden.

The lease begins in March with a 100% consumer price inflation indexation. This will be reviewed annually and includes a further five-year extension option.

Tritax Eurobox said the rent has been agreed at 3% above the estimated rental value as of September and 20% above the underwrite level.

Among London's small-caps, Topps Tiles lost 5.6%.

The retailer said sales in the 13 weeks ended December 30 were down 4.0% from a year earlier, with like-for-like sales down 7.1%.

It explained that trading in the first quarter reflected the ongoing challenges to discretionary consumer spending, particularly those impacting on businesses serving the repair, maintenance and improvement sector.

Topps Tiles expects its full-year profits to be weighted towards the second half, based on a number of factors including the timing of the holiday pay accrual, higher energy usage in the first half and general trading in the first half.

In the US on Wednesday, Wall Street ended lower, with the Dow Jones Industrial Average and the S&P 500 both down 0.8%, while the Nasdaq Composite was down 1.2%.

Federal Reserve officials late Wednesday concluded that interest rate cuts are likely in 2024, although they deemed it would be appropriate to maintain a restrictive stance "for some time," according to minutes of December's meeting.

"In discussing the policy outlook, participants viewed the policy rate as likely at or near its peak for this tightening cycle, though they noted that the actual policy path will depend on how the economy evolves," the minutes stated.

The minutes indicated increased optimism among participants about the path of inflation, noting "clear progress". The committee expressed a willingness to cut the benchmark lending rate in 2024 should that trend continue, though the timing of such a move remained uncertain.

Asian markets largely tracked US stocks into the red, the Nikkei 225 index in Tokyo closed down 0.5%. In China, the Shanghai Composite closed down 0.4%, while the Hang Seng index in Hong Kong was marginally down. The S&P/ASX 200 in Sydney closed down 0.4%.

China's services sector expanded at a faster pace at the end of 2023, according to the latest survey data. The Caixin services purchasing managers' index rose to 52.9 points from 51.5 in November, climbing further above the 50-point no-change mark.

Japanese manufacturing continued to contract in December. The au Jibun Bank manufacturing PMI fell to 47.9 from 48.3 in November, indicating a worsening downturn.

Gold was quoted at USD2,046.61 an ounce early Thursday, higher than USD2,038.89 on Wednesday.

On AIM, Angle soared 38%, after it unveiled "breakthrough" clinical results from DNA molecular analysis of cancer patient blood samples that "provide a unique insight into the progression of each patient's cancer and how this may be treated".

The medical diagnostics firm said the results "highlight the potential for the Parsortix system to identify key variants [of] DNA mutations missed by other approaches to help guide treatment decisions."

Still to come on Thursday's economic calendar, the services PMI for the UK will be released at 0930 GMT. Survey data will also be released for the EU and Germany shortly, followed by the US at 1445 GMT. Consumer price inflation data for Germany is released at 1300 GMT.

Two US jobs data releases also come out in the afternoon: the ADP jobs report at 1315 GMT and initial jobless claims at 1330 GMT.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.